Oxford launches major trial: can CBD oil boost standard psychosis treatment?
NCT ID NCT06778564
Summary
This study aims to see if adding cannabidiol (CBD), a non-intoxicating compound from cannabis, to standard antipsychotic medication can improve symptoms in young adults experiencing their first episode of psychosis. It will involve 250 participants aged 16-40 who have not responded well to their first antipsychotic drug. For 6 weeks, half will receive CBD oil and half a placebo, in addition to their ongoing medication, to compare effects on symptoms, functioning, and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSYCHOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Cambridgeshire and Peterborough NHS Foundation Trust
Cambridge, United Kingdom
Contact Email: •••••@•••••
-
Charité Universitätsmedizin
Berlin, Germany
Contact
-
Geha Mental Health Center
Petah Tikva, Israel
Contact
-
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Contact
-
Hospital Universitario Virgen del Rocío
Seville, Spain
Contact
-
Ludwig-Maximilian-University Munich
Munich, Germany
Contact Email: •••••@•••••
-
MedUni Vienna
Vienna, Austria
Contact
-
National and Kapodistrian University of Athens
Athens, Greece
Contact
-
Oxford Health NHS Foundation Trust
Oxford, United Kingdom
Contact
-
Psychiatric University Hospital (PUK), Zurich
Zurich, Switzerland
Contact
-
Shalvata Mental Health Center
Hod HaSharon, Israel
Contact
-
Sheba Medical Centre
Ramat Gan, Israel
Contact
-
Stichting Amsterdam UMC
Amsterdam, Netherlands
Contact
-
University Hospital Cologne
Cologne, Germany
Contact
-
University of Augsburg
Augsburg, Germany
Contact
-
University of Campania 'Luigi Vanvitelli'
Naples, Italy
Contact
-
West London NHS Trust
London, United Kingdom
Conditions
Explore the condition pages connected to this study.